title: Which basal insulin should be used in patients with type 2 diabetes mellitus?
abstract: The initiation of insulin therapy is a significant event for patients with diabetes and the physicians who care for them. Reluctance to begin insulin is multifactorial, with major stumbling blocks being the perceived complexity of insulin and fear of hypoglycemia. Recent guidelines supporting earlier introduction of insulin to achieve glycemic goals in patients with type 2 diabetes mellitus will require that traditional approaches to insulin therapy be altered and a new paradigm be introduced into clinical practice. In particular, an understanding of the role of basal insulin in the regulation of glucose and the development of strategies to implement basal insulin therapy can provide a transition that is rational and highly effective in most patients. The strategy also offers a unique approach to diabetes education that permits a focused and patient-specific correction to glucose abnormalities.
authors.affiliation: Division of Endocrinology and Metabolism, Virginia Commonwealth University, North Hospital, 1300 E. Marshall Street, Richmond, VA 23298, USA. jclore@mcvh-vcu.edu
authors.forename: John N
authors.initials: JN
authors.lastname: Clore
authors.forename: Linda
authors.initials: L
authors.lastname: Thurby-Hay
mesh_terms: D000284:Administration, Oral; D003131:Combined Modality Therapy; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000145:classification / Q000627:therapeutic use; D007328:Insulin / Q000031:analogs & derivatives / Q000145:classification / Q000627:therapeutic use*; D000069057:Insulin Detemir; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine; D000069057:Insulin Detemir